Alignment targets at least 20% 2027 top-line growth while lowering 2026 adjusted EBITDA outlook to no less than $100M

• “For the third quarter 2026, health plan membership of 301,200 represented growth of 31% year-over-year and drove overall revenue of approximately $1.4 billion, a 37% increase year-over-year,” said (Founder, Chairman & CEO John Kao), while noting “adjusted EBITDA was $22 million within the range of our guidance.”

• (CEO Kao) attributed the quarter’s profitability pressure to operational and medical cost drivers tied to scaling: “During this transitional period, we experienced greater volatility in claims processing… we identified a notable increase in aggressive provider appeal and disputes in our paid claims data,” and also saw “pockets of higher costs… such as catastrophic cases and skilled nursing.”

• (CEO Kao) described mitigation steps and emphasized conservatism in the updated outlook: “We acted swiftly… to build out a more robust payment integrity function,” and “we are taking a prudent approach… and assume that higher costs in the third quarter will continue to weigh on our results for the remainder of the year.”

• (Chief Financial Officer James Head) reiterated the Q3 performance mix and cost drivers: “Third quarter adjusted gross profit of $142 million represented an adjusted MBR of 89.5%,” adding that “we also observed a notable increase in provider-led appeals and disputes… along with elevated costs within our skilled nursing and catastrophic case categories.”

Outlook

• (CFO Head) guided Q4 2026 to “health plan membership to be no less than 305,000 members, revenue of no less than $1.32 billion, adjusted gross profit of no less than $104 million and adjusted EBITDA of no less than negative $28 million,” and guided full-year 2026 to “revenue of no less than $5.25 billion, adjusted gross profit of no less than $575 million and adjusted EBITDA of no less than $100 million.”

• (CEO Kao) framed the guide as a deliverable reset: “Given this position, we lowered our annual guidance to no less than adjusted gross profit of $575 million and adjusted EBITDA of $100 million… the guidance we have provided today is a guidance that we are confident in delivering.”

• Compared with Q2 2026 guidance, the company moved from Q2’s full-year adjusted EBITDA range of $145 million to $163 million and adjusted gross profit range of $630 million to $650 million to Q3’s “no less than” floors of $100 million and $575 million, respectively.

• Analyst-estimate comparisons were not included because the estimates tag did not provide fields in the required validated format.

Financial Results

• (CEO Kao) reported Q3 2026 operating metrics: membership of 301,200; revenue of approximately $1.4 billion; adjusted gross profit of $142 million; adjusted MBR of 89.5%; adjusted SG&A of $120 million (8.9% of revenue); and adjusted EBITDA of $22 million.

• (CFO Head) highlighted cash and leverage positioning: “We generated $158 million in operating cash flow during the first nine months of the year,” ended Q3 with “$743 million in cash, cash equivalents and short-term investments,” and reported “our funded leverage ratio… was 2.4x our trailing 12 months EBITDA.”

• (CFO Head) described Q4 guide assumptions as intentionally conservative: “we have assumed a continuation of the elevated medical claims expense we experienced in Q3 with no contemplation of the stabilizing trends we observed in both September and October,” and “while we are not including any benefits from the initiatives currently in progress, the cost of these initiatives are fully burdened in our guidance.”

Q&A

• Matthew Gillmor, KeyBanc: Asked how the Facets claims migration contributed to identifying higher costs; (CEO Kao) said, “It created volatility,” adding “the amount of appeals has dropped off significantly in August, September and October,” but the company is “being extra careful.”

• Joaquin Eduardo Martinez, BofA Securities: Asked about 2027 bid positioning and membership diversification; (CEO Kao) said the company “made some changes with respect to certain networks” and product growth pacing, and added on Stars concentration risk, “California has got so big that we just have to continue to invest in automation.”

• John Stansel, JPMorgan: Asked about the ‘27 “jumping off point” given the back-half guide; (CFO Head) said guidance assumes “higher appeals and disputes at… a peak rate” and does not assume “any favorability from payment integrity,” while (CEO Kao) cautioned, “I would strongly advise not to use the Q4 MLR as an annualized starting point for '27.”

• Justin Lake, Wolfe: Pressed on Q4 MBR and SG&A cadence; (CFO Head) cited Part D seasonality and “a pretty full run rate of these costs,” while (CEO Kao) emphasized, “the operative word… is prudence.”

• Michael Ha, Baird: Asked about Stars recovery milestones and the funding headwind; (CEO Kao) said on mitigation sizing, “Let us get back to you on that one, please,” and stated early AEP impact was limited: “The answer, it has not.”

• Scott Fidel, Goldman Sachs: Asked about delegation/risk sharing levers into 2028; (CEO Kao) said inpatient acute UM de-delegation is “about 80% through our process” and called preservice UM and care navigation “the next frontier.”

• Matthew Shea, Needham: Asked detailed HOS remediation and member-level differences; (CEO Kao) responded, “I need to get back to you as a follow-up.”

• Ye Yuan, Barclays: Asked about reserve variability and investment levels; (CFO Head) said, “we feel very good about our reserves,” noted reserves are “essentially at 99% run out on those dates of service,” and added, “We haven't changed any of our investments that we called out in Q2.”

Sentiment Analysis

• Analyst sentiment was slightly negative to skeptical, with repeated probing on the guide cut, durability of medical cost stabilization, Q4 conservatism, and Stars economics; management faced multiple requests for quantification that drew deferrals such as “Let us get back to you on that one, please.”

• Management sentiment was neutral to slightly positive in tone but defensive on starting-point framing for 2027, repeatedly stressing conservatism; (CEO Kao) used directive language: “I would strongly advise not to use the Q4 MLR as an annualized starting point for '27,” and (CFO Head) emphasized that guidance includes “no contemplation of the stabilizing trends.”

• Versus Q2’s more confident tone around being “well on track” and having “strong visibility,” Q3’s tone shifted toward remediation and delivery confidence, with (CEO Kao) characterizing the period as “a bit of a reset.”

Quarter-over-quarter Comparison

• Q2 emphasized margin expansion, embedded earnings, and investments “inside the financial commitments,” while Q3 centered on claims migration disruption, provider disputes, and medical cost pockets, alongside a reduced full-year profitability floor.

• Guidance language moved from Q2 range-based targets to Q3 minimum-floor commitments, with (CEO Kao) explicitly stressing deliverability: “a guidance that we are confident in delivering.”

• Analyst focus shifted from investment timing and seasonality in Q2 to Q3’s cost trend drivers (appeals/disputes, SNF, catastrophic cases), the reliability of Q4 assumptions, and the economic implications of a 3.5-star California HMO contract.

Risks and Concerns

• (CEO Kao) cited operational risk from the claims migration: “anybody that's gone through one of these conversions knows it's a messy process,” and described provider behavior risk: “aggressive provider appeal and disputes.”

• (CEO Kao) flagged medical cost volatility drivers including “catastrophic cases and skilled nursing,” and stated mitigation via “prepaid claims edits,” “more rigorous post-pay review,” and targeted clinical best-practice investments.

• (CEO Kao) highlighted Stars risk concentration in California: “our California HMO contract earned a 3.5 star rating, which was below our expectations,” and said remediation includes “data and workflow opportunities,” provider/member engagement, and accelerated HEDIS gap closure.

Final Takeaway

Management described Q3 as a quarter where membership and revenue growth continued, but elevated medical cost trends—linked to claims-system migration volatility, provider disputes, and higher SNF and catastrophic costs—drove a more conservative stance for the rest of 2026, including lowering full-year profitability expectations and guiding to a negative Q4 adjusted EBITDA. Executives said they are prioritizing payment integrity, clinical execution, and Stars remediation—especially in California—while maintaining a stated goal of at least 20% top-line growth into 2027 and positioning for new market entries including San Antonio and Charlotte.

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.